Safety profile of hydroxychloroquine and azithromycin combined treatment in COVID-19 patients.
作者信息
Gautret Philippe, Honoré Stéphane, Lagier Jean-Christophe, Raoult Didier
机构信息
IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France.
Service Pharmacie, Hôpital Timone, AP-HM, Marseille, France; Laboratoire de Pharmacie Clinique, Aix Marseille Université, Marseille, France.
出版信息
Int J Antimicrob Agents. 2021 Jan;57(1):106236. doi: 10.1016/j.ijantimicag.2020.106236.
Abstract
摘要
相似文献
1
Safety profile of hydroxychloroquine and azithromycin combined treatment in COVID-19 patients.羟氯喹啉与阿奇霉素联合治疗COVID-19患者的安全性概况。
Int J Antimicrob Agents. 2021 Jan;57(1):106236. doi: 10.1016/j.ijantimicag.2020.106236.
2
Clinical efficacy and safety profile of hydroxychloroquine and azithromycin against COVID-19.羟氯喹啉和阿奇霉素治疗新型冠状病毒肺炎的临床疗效及安全性概况
Int J Antimicrob Agents. 2021 Jan;57(1):106242. doi: 10.1016/j.ijantimicag.2020.106242.
3
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited.羟氯喹和阿奇霉素用于治疗新型冠状病毒肺炎：重新审视一项开放标签非随机临床试验的结果
Int J Antimicrob Agents. 2021 Jan;57(1):106243. doi: 10.1016/j.ijantimicag.2020.106243.
4
Advanced statistical methods and designs for clinical trials for COVID-19.用于新型冠状病毒肺炎临床试验的先进统计方法与设计
Int J Antimicrob Agents. 2021 Jan;57(1):106167. doi: 10.1016/j.ijantimicag.2020.106167.
5
Effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial.羟氯喹治疗新型冠状病毒肺炎的疗效评估：一项开放标签非随机临床试验的二次分析
Int J Antimicrob Agents. 2021 Jan;57(1):106172. doi: 10.1016/j.ijantimicag.2020.106172.
6
Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis.羟氯喹和阿奇霉素对新型冠状病毒肺炎患者严重急性呼吸综合征冠状病毒2清除率的影响：一项荟萃分析
Int J Antimicrob Agents. 2021 Jan;57(1):106240. doi: 10.1016/j.ijantimicag.2020.106240.
7
Use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature.近期文献不支持将羟氯喹与阿奇霉素联合用于新冠肺炎患者。
Int J Antimicrob Agents. 2021 Jan;57(1):106174. doi: 10.1016/j.ijantimicag.2020.106174.
8
Letter to the editor about "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".致编辑的信：关于“羟氯喹和阿奇霉素作为治疗新型冠状病毒肺炎的药物：一项开放标签非随机临床试验的结果”
Int J Antimicrob Agents. 2021 Jan;57(1):106171. doi: 10.1016/j.ijantimicag.2020.106171.
9
Referring to the study: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial.参考研究：《羟氯喹和阿奇霉素治疗新型冠状病毒肺炎：一项开放标签非随机临床试验的结果》
Int J Antimicrob Agents. 2021 Jan;57(1):106176. doi: 10.1016/j.ijantimicag.2020.106176.
10
Focus on clinical outcomes of "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".关注“羟氯喹和阿奇霉素治疗新型冠状病毒肺炎：一项开放标签非随机临床试验的结果”的临床结局。
Int J Antimicrob Agents. 2021 Jan;57(1):106175. doi: 10.1016/j.ijantimicag.2020.106175.
引用本文的文献
1
Response to the use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature.近期文献不支持将羟氯喹与阿奇霉素联合用于治疗COVID-19患者。
Int J Antimicrob Agents. 2021 Jan;57(1):106241. doi: 10.1016/j.ijantimicag.2020.106241.
本文引用的文献
1
Combination of Hydroxychloroquine Plus Azithromycin As Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity.羟氯喹联合阿奇霉素作为 COVID-19 患者潜在治疗方法：安全性概况、药物相互作用以及毒性管理。
Microb Drug Resist. 2021 Mar;27(3):281-290. doi: 10.1089/mdr.2020.0232.
2
Doxycycline as an Alternative to Azithromycin in Elderly Patients.多西环素作为老年患者阿奇霉素的替代药物
Int J Antimicrob Agents. 2021 Jan;57(1):106168. doi: 10.1016/j.ijantimicag.2020.106168.
3
Antimalarial drugs inhibit the replication of SARS-CoV-2: An in vitro evaluation.抗疟药物抑制 SARS-CoV-2 的复制：体外评价。
Travel Med Infect Dis. 2020 Sep-Oct;37:101873. doi: 10.1016/j.tmaid.2020.101873. Epub 2020 Sep 8.
4
Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis.法国马赛接受羟氯喹/阿奇霉素和其他方案治疗的 3737 例 COVID-19 患者的结局：一项回顾性分析。
Travel Med Infect Dis. 2020 Jul-Aug;36:101791. doi: 10.1016/j.tmaid.2020.101791. Epub 2020 Jun 25.
5
Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France.羟氯喹和阿奇霉素联合治疗 COVID-19 患者：法国马赛 1061 例回顾性分析。
Travel Med Infect Dis. 2020 May-Jun;35:101738. doi: 10.1016/j.tmaid.2020.101738. Epub 2020 May 5.
Zotero 插件